Opinion

Video

Tildrakizumab for Nail Psoriasis: Key Findings From AAD 2025

A panelist discusses how new data from the 2025 American Academy of Dermatology Annual Meeting (AAD 2025) demonstrates tildrakizumab’s efficacy in treating nail psoriasis, with the 100-mg dose showing significant improvements in mNAPSI 75 and ViSENPsO responses at week 28 compared with placebo, potentially addressing a critical unmet need in psoriasis treatment.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
1 expert in this video
4 experts in this video
4 experts in this video
Dr Caroline Vovan
1 expert is featured in this series.
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo